Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology Investing.com

• License agreement focused on the development of one ADC program
• Using Synaffix GlycoConnect ® , HydraSpace ® and toxSYN ® ADC technologies to improve efficacy, tolerability and targeting

AMSTERDAM, January 9, 2025 /PRNewswire/ — Synaffix BV (“Synaffix”), a Lonza (SWX: LONN) company focused on commercializing its clinical platform technology for the development of best-in-class therapeutic index antibody-drug conjugates (ADCs), today announced that it has licensed its ADC technology to Mitsubishi Tanabe Pharma Corporation (“MTPC”), the pharmaceutical arm of Mitsubishi Chemical Group (“MCG”).

Synaffix is ​​responsible for manufacturing components related to its proprietary technologies, and MTPC is responsible for research, development, manufacturing and commercialization of ADCs.

Peter van de Sandemanager of Synaffix, said: “This latest licensing agreement with MTPC underscores the appeal of our leading ADC technology offering. MTPC is our key collaborator expanding our presence in the APAC region and we are excited to work alongside such a large and respected corporation to make a tangible difference to patients in areas of high unmet medical need.”

About Synaffix

Synaffix BV is a biotechnology company that enables ADC product candidates to use its clinical-stage specific ADC technology platform based on GlycoConnect ® , HydraSpace ® and toxSYN ® technologies, which together enable each antibody company to develop proprietary best-in-class ADC products under a single license from Synaffix .

The Synaffix platform allows for a quick time frame to the clinic thanks to an established supply chain of technological components. Synaffix has granted patents for its technology. Synaffix’s business model is the external licensing of specific technology, as demonstrated through its partnership offering.

Synaffix completely took over Lonzo in the year June 2023.

For more information on the Synaffix ADC platform technology, please visit: https://synaffix.com/platform/technology/

About Lonza

Lonza is one of the world’s largest organizations for the production of health products. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutraceutical companies bring their treatments to market. United by our vision to bring every therapy to life, we support our clients with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our clients to develop and commercialize their therapeutic discoveries, enabling their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet the complex needs of our customers. Our company achieved sales of CHF 3.1 billion with CORE EBITDA of CHF 893 million in the semester of 2024. More at www.lonza.com

Follow @Lonza at LinkedIn

Follow @LonzaGroup at X

About Mitsubishi Tanabe Pharma Corporation (MTPC)

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharmaceutical arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, with a focus on ethical medicines. MTPC is headquartered in Doshomachi, Osakabirthplace of Japan pharmaceutical industry. MTPC sets a MISSION “Creating hope for all who face illness”. To this end, MTPC works in the areas of diseases of the central nervous system, immune inflammation, diabetes and kidney and cancer. MTPC focuses on “precision medicine” to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop “pill solutions” to address specific patient problems based on therapeutic medicine, including disease prevention, pre-symptomatic disease care, exacerbation prevention and prognosis. For more information, please visit https://www.mt-pharma.co.jp/e/.